CD4 and neoplasm: Experimental results have shown that TECs can induce immune responses of tumor antigen-specific CD8+ T cells through the PD-1/PD-L1 pathway and evade tumor immunity by regulating immunosuppressive CD4+ T cells in an antigen-specific manner (112).